abatacept造句

• It differs from abatacept ( Orencia ) by only 2 amino acids.
• Abatacept binds to the CD80 and CD86 molecule, and prevents the second signal.
• Abatacept in a subcutaneous administration form has been approved by USFDA, for self-administration by the patient.
• What is known to work is Abatacept, an CD152-Ig used in treating rheumatoid arthritis and juvenile idiopathic arthritis.
• Abatacept appears effective for RA with 20 % more people improving with treatment than without but long term safety studies are yet unavailable.
• Abatacept is a fusion protein composed of the Fc region of the immunoglobulin IgG1 fused to the extracellular domain of CTLA-4.
• These agents used to treat rheumatoid arthritis include : tumor necrosis factor alpha ( TNF? ) blockers T cell costimulation blocker such as abatacept among others.
• Regular administration of abatacept improved the patient s severe anemia and diarrhea ( 3L / day ) and brought 3-year-long hospitalization to an end.
• Experimental therapies under investigation include endothelin receptor antagonsits, tyrosine kinase inhibitors, beta-glycan peptides, halofuginone, basiliximab, alemtuzumab, abatacept and haematopoietic stem cell transplantation.
• The following drugs are considered as DMARDs : methotrexate, hydroxychloroquine, sulfasalazine, leflunomide, TNF-alpha inhibitors ( certolizumab, infliximab and etanercept ), abatacept, and anakinra.
• Abatacept was developed by Bristol-Myers Squibb and is licensed in the United States for the treatment of rheumatoid arthritis in the case of inadequate response to anti-TNF? therapy.
• The ACCESS phase II clinical trial, sponsored by the National Institute of Allergy and Infectious Diseases is ( ) studying abatacept treatment in lupus nephritis when used in combination with cyclophosphamide therapy.
• A recent study treated a Korean CHAI disease patient with CTLA4 mimetic, CTLA4-Ig ( e . g . . abatacept ) and was able to control immune activity and improve patient symptoms.
• Abatacept consists of a fusion protein of the extracellular domain of CTLA-4 and human IgG1, binds to the B7 protein on the APC and prevents it from delivering the co-stimulatory signal to the T cell.
• Many medications are being studied, including abatacept, MEXIS / M6S, triamcinolone, secukinumab, tralonkinumab, apremilast, botulinum toxin, INCB018424, bimatoprost, clobetasol, AS101, autologous platelet-rich plasma, topical minoxidil, and nitric oxide gel.
• IVIG is used for CIDP and GBS . Specific immunomodulatory therapies, such as the TNF? antagonists ( e . g . etanercept ), the B cell depleting agent rituximab, the anti-IL-6 receptor tocilizumab and the costimulation blocker abatacept have been shown to be useful in treating RA . Some of these immunotherapies may be associated with increased risk of adverse effects, such as susceptibility to infection.